a study on Short Bowel Syndrome
This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for patients with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in patients with SBS. SBS patients treated and not treated with teduglutide will be enrolled.
Short Bowel Syndrome SBS teduglutide Gattex
This is an observational registry study. Data will be collected during routine consultations and clinical staff will enter this information into a system at baseline(when a patient consents into the study) and approximately every 6 months following. Each patient will be followed for at least 10 years.
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT01990040.
© The Regents of the University of California